Resources
46 Results (showing 31 - 40)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 8/4/2021 (updated 4/2/2024)
This program brief highlights the Alliance for Prevention and Wellness (APW) use of Overdose Detection Mapping Application Program (ODMAP) data to target a broad range of substance use prevention and education activities to ZIP codes with the highest rate of overdoses. Source: Bureau of Justice Assistance (BJA)-Supported Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP).
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Deliverable Guidance: PIMS
Kathleen Meyers, PhD, and Rebecca Schachtner, PhD, JBS International
Posted 11/4/2020 (updated 4/3/2024)
The Council of State and Territorial Epidemiologists established the PMP Subcommittee to provide a platform for information exchange and addressing the need for a standardized metrics for opioid surveillance using PMP data. PMP group members identified a need to provide guidance for new PMP data users. Group members collaborated to write and develop a very comprehensive two-part How To Guide that provides instructions for new PMP data users.
Posted 11/4/2020 (updated 4/3/2024)
The updated 2020 National Rural Health Day "Key Messages & Data Points" ePublication is full of rural-relevant data points that relate to the 3 NRHD key messages.
Posted 11/18/2020 (updated 4/3/2024)
Pharmacists can play an important role in improving access to medication for opioid use disorder (MOUD), especially for individuals living in rural areas where health care workforce shortages are pervasive. Learn how pharmacists can provide Medication Administration Services (MAS) and establish Collaborative Practice Agreements (CPA) in coordination with one or more treating health care providers.
Posted 12/9/2020 (updated 4/3/2024)
State policymakers are interested in learning about the most effective treatments to address OUD and avoid unintended consequences such as overdose events, mortality from overdose, and use of illicit and unregulated drugs. This article describes the lack of evidence surrounding the use of Medically Supervised Withdrawal as a standalone “treatment.”
Posted 10/14/2021 (updated 4/3/2024)
Representatives from the JBS/HRSA evaluation team presented information on Performance Improvement Measurement System deliverables and answer grantee questions.
Rebecca Schachtner, PhD, JBS International
Posted 10/14/2021 (updated 4/3/2024)
Presenters explained the role of RH in the continuum of care in this exciting and interactive presentation on emerging topics related to integrating social and medical models of recovery. They focused on emerging issues in rural America resulting from the pandemic, its impact on the rates of substance use disorder (SUD), and use of RH. Presenters emphasized funding for the development of RH, the role of partnerships within the recovery ecosystem, and promising practices involving cross-sector collaboration in housing, corrections, treatment, and recovery supports.
Milena Stott, LICSW, SUDP, The Fletcher Group
Erica Walker, CSW, TCADC, The Fletcher Group
Posted 11/11/2021 (updated 4/3/2024)
Performance Improvement Measurement System